Literature DB >> 20503454

Anti-inflammatory efficiency of levobupivacaine in an experimental colitis model.

Ugur Duman1, Aysun Yilmazlar, Ersin Ozturk, Sibel Aker, Emre Sarandol, Tuncay Yilmazlar.   

Abstract

AIM: To investigate the efficiency of levobupivacaine in treating experimentally induced colitis in rats.
METHODS: Colitis was induced by trinitrobenzene sulfonic acid and ethanol in 30 rats under general anesthesia, and 10 rats were used as a sham group. Subsequent to induction of colitis, rats were divided into three groups; budesonide group received 0.1 mg/kg budesonide, levobupivacaine group received 10 mg/kg levobupivacaine and saline group received 1 mL saline solution via rectal route for 7 d. In the sham group, only routine rectal catheterization was performed without use of any material. At the end of 7 d, laparotomy and total colectomy were performed for histopathological examination in all rats and blood samples were drawn for measurement of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 following cardiac puncture. Macroscopic and microscopic evaluations of the specimens were performed by a pathologist blinded to group assignment of the rats.
RESULTS: Weight loss (P = 0.016) and macroscopic examination scores (P = 0.001) were significantly higher in saline group than others. Histopathological scoring was comparable between all colitis groups (P = 0.350). There was no significant difference in TNF-alpha levels and IL-6 levels (P = 0.150).
CONCLUSION: The significant improvement in macroscopic scores suggests that levobupivacaine may have topical anti-inflammatory effects in an experimental colitis model; however, this finding was not supported by microscopic findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503454      PMCID: PMC2877184          DOI: 10.3748/wjg.v16.i20.2537

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

Review 1.  Recent developments in the immunology of inflammatory bowel disease.

Authors:  T T MacDonald; G Monteleone; S L Pender
Journal:  Scand J Immunol       Date:  2000-01       Impact factor: 3.487

Review 2.  Treatment of distal colitis with local anaesthetic agents.

Authors:  Stellan Björck; Annica Dahlström; Håkan Ahlman
Journal:  Pharmacol Toxicol       Date:  2002-04

3.  A meta-analysis of the role of smoking in inflammatory bowel disease.

Authors:  B M Calkins
Journal:  Dig Dis Sci       Date:  1989-12       Impact factor: 3.199

4.  Ropivacaine gel in active distal ulcerative colitis and proctitis -- a pharmacokinetic and exploratory clinical study.

Authors:  E Arlander; A Ost; D Stahlberg; R Lofberg
Journal:  Aliment Pharmacol Ther       Date:  1996-02       Impact factor: 8.171

5.  Surgical management of complications of steroid therapy.

Authors:  A G Diethelm
Journal:  Ann Surg       Date:  1977-03       Impact factor: 12.969

6.  Topical treatment of ulcerative proctitis with lidocaine.

Authors:  S Björck; A Dahlström; H Ahlman
Journal:  Scand J Gastroenterol       Date:  1989-11       Impact factor: 2.423

7.  Effect of lidocaine on the function of immunocompetent cells. II. Chronic in vivo exposure and its effects on mouse lymphocyte activation and expression of immunity.

Authors:  R Dickstein; L Kiremidjian-Schumacher; G Stotzky
Journal:  Immunopharmacology       Date:  1985-06

8.  On the etiology of Crohn disease.

Authors:  D Mishina; P Katsel; S T Brown; E C Gilberts; R J Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Treatment of the mucosa with local anaesthetics in ulcerative colitis.

Authors:  S Björck; A Dahlström; L Johansson; H Ahlman
Journal:  Agents Actions       Date:  1992

10.  Functional voltage-gated sodium channels are expressed in human intestinal epithelial cells.

Authors:  Iris Barshack; Mia Levite; Alon Lang; Ella Fudim; Orit Picard; Shomron Ben Horin; Yehuda Chowers
Journal:  Digestion       Date:  2008-04-07       Impact factor: 3.216

View more
  2 in total

1.  Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.

Authors:  Abhijit A Date; Gilad Halpert; Taarika Babu; Jairo Ortiz; Pranjali Kanvinde; Peter Dimitrion; Janani Narayan; Hannah Zierden; Kalpana Betageri; Olivia Musmanno; Helen Wiegand; Xinglu Huang; Sanjeev Gumber; Justin Hanes; Laura M Ensign
Journal:  Biomaterials       Date:  2018-09-07       Impact factor: 12.479

2.  Peripheral surgical wounding and age-dependent neuroinflammation in mice.

Authors:  Zhipeng Xu; Yuanlin Dong; Hui Wang; Deborah J Culley; Edward R Marcantonio; Gregory Crosby; Rudolph E Tanzi; Yiying Zhang; Zhongcong Xie
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.